Chu Grenoble Alpes

The trials here

What the 25 trials at this site are about, from their registry records.

Conditions

• Obesity4 trials
• Stroke4 trials
• Chronic kidney disease3 trials
• Type 2 diabetes3 trials
• Coronary artery disease2 trials
• Heart failure2 trials
• Lung cancer2 trials
• Brain aneurysm1 trial
• Crohn's disease1 trial
• Down syndrome1 trial
• High blood pressure1 trial
• HIV1 trial
• and 12 more

Phase

• Phase 39 trials
• Phase 21 trial

Status

• Recruiting8 trials
• Not yet recruiting7 trials
• Active, not recruiting5 trials
• Completed4 trials
• Terminated1 trial

Lead sponsor

• University Hospital, Grenoble7 trials
• Eli Lilly and Company6 trials
• Alfasigma S.p.A.1 trial
• ANRS, Emerging Infectious Diseases1 trial
• Assistance Publique - Hôpitaux de Paris1 trial
• and 9 more

Running trials

• Not yet recruiting

  Real World Positioning of Tyrosine Kinase Inhibitors (TKIs) Within Systemic Treatment Strategies for Advanced Neuroendocrine Tumors (NETs)

  NCT07890012· Hospices Civils de Lyon· Source

  Contact: Dr Victoire GRANGER

• Not yet recruiting

  A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk

  NCT07900633· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

  NCT07705568· Phase 2· Eyevensys· Source

• Not yet recruiting

  Coronary Artery Disease Screening in Patients With Chronic Kidney Disease

  NCT07585695· University Hospital, Grenoble· Source

  Contact: Gilles Barone Rochette, PI

• Not yet recruiting

  Qualitative Exploration of Key Symptoms of Stricturing Crohn's Disease: Toward the Development of a Clinical Assessment Score.

  NCT07441629· University Hospital, Grenoble· Source

  Contact: Anna Borowik, PhD

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Real Life Data From Hypertensive Patients Treated With Renal Denervation in Current Practice in France- French RENal Denervation Registry

  NCT07206030· University Hospital, Grenoble· Source

  Contact: Olivier ORMEZZANO, Doctor of medicine

• Recruiting

  EURO-STIM Registry

  NCT06971796· Inspire Medical Systems, Inc.· Source

  Contact: Prof. Renaud Tamisier

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Denis Moro-Sibilot (principal investigator)

• Active, not recruiting

  The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

  NCT06383390· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer

  NCT06216496· University Hospital, Grenoble· Source

  Contact: Cécile Bétry

• Recruiting

  Down Syndrome, Physical Activity and Sleep Apnea

  NCT06061562· University Hospital, Grenoble· Source

  Contact: Véronique BRICOUT, PHD

• Recruiting

  Endoscopic Sutured Gastroplasty with Endomina® Device Versus Standard of Care in Patients with Type 2 Diabetes and Class I Obesity: a Multi-center, Randomized Controlled Trial

  NCT05516576· University Hospital, Grenoble· Source

  Contact: Anne-Laure BOREL, MDD

• Not yet recruiting

  tDCS for Cognitive Impairment Associated With Recent-onset Schizophrenia

  NCT05440955· University Hospital, Grenoble· Source

  Contact: Colombat Julien

• Active, not recruiting

  A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

  NCT05556512· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Cardioverter DefIbriIlator PlacEMent for priMary Prevention of Sudden cArdiac Death in Patients Older Than 70 Years

  NCT05373940· Assistance Publique - Hôpitaux de Paris· Source

  Contact: Pascal DEFAYE, MD, PhD

• Active, not recruiting

  Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion

  NCT05069558· Occlutech International AB· Source

• Recruiting

  Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform

  NCT04927156· Balt Extrusion· Source

  Contact: Kamel Boubagra, MD (principal investigator)

• Active, not recruiting

  A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

  NCT02411448· Phase 3· Eli Lilly and Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease2 recruiting
• Obesity2 recruiting
• Stroke2 recruiting
• Type 2 diabetes2 recruiting
• Brain aneurysm1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• Down syndrome1 recruiting
• Heart failure1 recruiting
• High blood pressure1 recruiting
• Lung cancer1 recruiting
• Macular degeneration1 recruiting
• Neuroendocrine tumours1 recruiting
• Obstructive sleep apnoea1 recruiting
• Ovarian cancer1 recruiting
• Schizophrenia1 recruiting

Closed trials

• Terminated

  Telemonitoring Platform "CUREETY TECHCARE" vs Standard of Care for mTBNC Patients Initiating a First-line Treatment

  NCT06505018· UNICANCER· Source

• Completed

  Aging With HIV and Neurocognitive Decline, a Follow-up Study

  NCT05385588· ANRS, Emerging Infectious Diseases· Source

• Completed

  Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

  NCT04777539· Nantes University Hospital· Source

• Completed

  Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer

  NCT03941093· Phase 3· Kyntra Bio· Source

• Completed

  Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

  NCT02914535· Phase 3· Alfasigma S.p.A.· Source